Evaxion A (EVAX) Non-Current Receivables (2020 - 2025)
Evaxion A posted quarterly Non-Current Receivables of $866000.0 for Q4 2025, down 43.77% year-on-year from $1.5 million in Q4 2024, and little changed on a QoQ basis from $864000.0 in Q2 2025.
Evaxion A (EVAX) has 6 years of Non-Current Receivables data on file, last reported at $866000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Receivables fell 43.77% year-over-year to $866000.0; the trailing twelve-month figure through Dec 2025 stood at $866000.0 (down 43.77% YoY), and the FY2025 full-year result was $866000.0, down 43.77% from the prior year.
- Non-Current Receivables for Q4 2025 stood at $866000.0, roughly flat from $864000.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $1.5 million in Q4 2024 and bottomed at $549000.0 in Q2 2021.
- The 5-year median for Non-Current Receivables is $808500.0 (2023), against an average of $842500.0.
- The widest annual swing landed in 2021, when Non-Current Receivables soared 100.48%; it then tumbled 43.77% in 2025.
- A 5-year view of Non-Current Receivables shows it stood at $838000.0 in 2021, then declined by 5.85% to $789000.0 in 2022, then increased by 3.3% to $815000.0 in 2023, then jumped by 88.96% to $1.5 million in 2024, then sank by 43.77% to $866000.0 in 2025.
- The last three Non-Current Receivables figures came in at $866000.0 (Q4 2025), $864000.0 (Q2 2025), and $1.5 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 866,000.00 |
| Jun 30, 2025 | 864,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Jun 30, 2024 | 790,000.00 |
| Dec 31, 2023 | 815,000.00 |
| Jun 30, 2023 | 802,000.00 |
| Dec 31, 2022 | 789,000.00 |
| Jun 30, 2022 | 768,000.00 |
| Mar 31, 2022 | 821,000.00 |
| Dec 31, 2021 | 838,000.00 |
| Sep 30, 2021 | 668,000.00 |
| Jun 30, 2021 | 549,000.00 |
| Dec 31, 2020 | 418,000.00 |